Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined

Author： Adis International Limited  

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.22, Iss.11, 2006-11, pp. : 1-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anagrelide: A Review of its Use in the Management of Essential Thrombocythaemia

By Wagstaff Antona J.   Keating Gillian M.  

Drugs, Vol. 66, Iss. 1, 2006-01 ,pp. : 111-131

Adis International

Access to resources Recommend Favorite

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

By Petrides Petro E  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1781-1798

Informa Healthcare

Access to resources Recommend Favorite

Anagrelide/hydroxycarbamide: Essential thrombocythaemia transformation to AML or MDS: 17 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1334, 2011-01 ,pp. : 8-9

Adis International

Access to resources Recommend Favorite

Essential thrombocythaemia in children: is a treatment needed?

By Randi Maria Luigia   Putti Maria Caterina  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 5, 2004-05 ,pp. : 1009-1014

Informa Healthcare

Access to resources Recommend Favorite

Anagrelide: a novel agent for the treatment of myeloproliferative disorders

By Pescatore S.L.   Lindley C.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 537-546

Informa Healthcare

Access to resources Recommend Favorite